Regions
MAIN/REGIONS
regions/
Regions
  1. Americas
  2. Asia & Oceania
  3. Europe
  4. Middle East & Africa
  1. Solutions
  2. Products
  3. Insights
  4. About
  5. Careers
  6. Contact Us
MAIN/search
MAIN/Solutions
Solutions/
SOLUTIONS
  • Research & Development
  • Real World Evidence
  • Commercialization
  • Safety & Regulatory Compliance
  • Technologies
LIFE SCIENCE SEGMENTS
HEALTHCARE SEGMENTS
THERAPEUTIC AREAS

Impacting People's Lives

"We strive to help improve outcomes and create a healthier, more sustainable world for people everywhere.

LEARN MORE
Harness the power to transform clinical development

Reimagine clinical development by intelligently connecting data, technology, and analytics to optimize your trials. The result? Faster decision making and reduced risk so you can deliver life-changing therapies faster.

Research & Development Overview
Research & Development Quick Links
Real World Evidence. Real Confidence. Real Results.

Generate and disseminate evidence that answers crucial clinical, regulatory and commercial questions, enabling you to drive smarter decisions and meet your stakeholder needs with confidence.

REAL WORLD EVIDENCE OVERVIEW
Real World Evidence Quick Links
See markets more clearly. Opportunities more often.

Elevate commercial models with precision and speed using AI-driven analytics and technology that illuminate hidden insights in data.

COMMERCIALIZATION OVERVIEW
Commercialization Quick Links
Service driven. Tech-enabled. Integrated compliance.

Orchestrate your success across the complete compliance lifecycle with best-in-class services and solutions for safety, regulatory, quality and medical information.

COMPLIANCE OVERVIEW
Safety & Regulatory Compliance Quick Links
Intelligence that transforms life sciences end-to-end.

When your destination is a healthier world, making intelligent connections between data, technology, and services is your roadmap.

TECHNOLOGIES OVERVIEW
Technology Quick Links
MAIN/Products
Products/
CLINICAL PRODUCTS
COMMERCIAL PRODUCTS
COMPLIANCE, SAFETY, REG PRODUCTS
REAL WORLD PRODUCTS

CASE STUDY

"Data in a Day

LEARN MORE
MAIN/Insights
Insights/
BLOGS, WHITE PAPERS & CASE STUDIES

Explore our library of insights, thought leadership, and the latest topics & trends in healthcare.

DISCOVER INSIGHTS
THE IQVIA INSTITUTE

An in-depth exploration of the global healthcare ecosystem with timely research, insightful analysis, and scientific expertise.

SEE LATEST REPORTS

INSTITUTE REPORT

"Global Trends in R&D 2025

READ MORE

EMEA Insights

"IQVIA thought leadership with a focus on EMEA.

Learn more

WHITE PAPER

"DCTs Deliver Big ROI

LEARN MORE

WHITE PAPER

"Capturing value at scale: The $4 billion RWE imperative

LEARN MORE
MAIN/About
About/
FEATURED INNOVATIONS
  • IQVIA Connected Intelligence™
  • IQVIA Healthcare-grade AI®
  • IQVIA AI Assistant
  • Human Data Science Cloud
  • IQVIA Innovation Hub
  • Decentralized Trials
  • Patient Experience Solutions with Apple devices
WHO WE ARE
NEWS & RESOURCES

INVESTOR RELATIONS

"Visit our investor relations site for more information.

LEARN MORE
Unlock your potential to drive healthcare forward

By making intelligent connections between your needs, our capabilities, and the healthcare ecosystem, we can help you be more agile, accelerate results, and improve patient outcomes.

LEARN MORE
IQVIA AI is Healthcare-grade AI

Building on a rich history of developing AI for healthcare, IQVIA AI connects the right data, technology, and expertise to address the unique needs of healthcare. It's what we call Healthcare-grade AI.

LEARN MORE
Meet the IQVIA AI Assistant

Your new expert analyst is here. Be at the forefront of data-driven decision-making with a new generative AI tool that enables you to interact with our products and solutions like never before. Get results you can trust, faster.

LEARN MORE
Your healthcare data deserves more than just a cloud.

The IQVIA Human Data Science Cloud is our unique capability designed to enable healthcare-grade analytics, tools, and data management solutions to deliver fit-for-purpose global data at scale.

LEARN MORE
Innovations make an impact when bold ideas meet powerful partnerships

The IQVIA Innovation Hub connects start-ups with the extensive IQVIA network of assets, resources, clients, and partners. Together, we can help lead the future of healthcare with the extensive IQVIA network of assets, resources, clients, and partners.

LEARN MORE
Proven, faster DCT solutions

IQVIA Decentralized Trials deliver purpose-built clinical services and technologies that engage the right patients wherever they are. Our hybrid and fully virtual solutions have been used more than any others.

LEARN MORE
IQVIA Patient Experience Solutions with Apple devices

Empowering patients to personalize their healthcare and connecting them to caregivers has the potential to change the care delivery paradigm.

LEARN MORE
MAIN/Careers
Careers/
IQVIA Careers
Featured Careers
Stay Connected

WE'RE HIRING

"At IQVIA your potential has no limits. We thrive on bold ideas and fearless innovation. Join us in reimagining what’s possible.

VIEW ROLES
MAIN/Contact Us
Contact Us/
Blog
Testing of biomarkers in Oncology
Biomarkers are indicators of a patient’s likelihood to respond to certain treatments. By testing for predictive biomarkers, oncologists can make more informed treatment decisions, leading to better patient outcomes.
IQVIA Belux
Mar 26, 2025
  • Blogs
  • Testing of biomarkers in Oncology

The landscape of oncology has been significantly transformed by the integration of biomarkers, a trend that has been accelerating since the introduction of targeted therapies in the late 1990s. Recent advancements have continued to highlight the critical role of biomarkers in personalizing cancer treatment and improving patient outcomes.

Solid tumor patients, particularly those with Breast Cancer and Non-Small Cell Lung Cancer (NSCLC), exhibit higher rates of biomarker testing compared to patients with hematological malignancies1. This disparity is largely due to the greater number of predictive biomarkers identified for solid tumors, which are linked to a wider array of targeted therapies. However, certain hematological cancers, such as Acute Lymphoblastic Leukemia (ALL) and Acute Myeloid Leukemia (AML), also show high testing rates for key biomarkers, reflecting the ongoing evolution in this field.

Figure 1The above table is a non-exhaustive list.

Sources: National Cancer Institute | Biomarker; Personalized Medicine. 2010;7(5):517-530; Immunother Cancer. 2020 Jul;8(2): e000953; Transl Cancer Res. 2015 Jun; 4(3): 256–269., Journal of Clinical Oncology, 2024, Vol. 42, pp. 123-130.Cancer Research, 2023, Vol. 83, pp. 456-462.; Nature Reviews Clinical Oncology, 2023, Vol. 20, pp. 789-798. The Lancet Oncology, 2022, Vol. 23, pp. 1012-1020. Journal of the National Cancer Institute, 2023, Vol. 115, pp. 234-240.

Notes: +: overexpression, mut: mutant, wt: wildtype, del: deletion, t(n;n), translocation; CLL: Chronic lymphocytic leukemia; RCC: Renal cell carcinoma; CRC: Colorectal cancer

Over the past decade, Phase III clinical trials have been predominantly focused on Breast Cancer and Non-Small Cell Lung Cancer (NSCLC), reflecting the high frequency of biomarker testing in these indications. Recent trends indicate a growing share of the predictive biomarker Phase III pipeline being occupied by Ovarian Cancer and Prostate Cancer trials, driven by the success of PARP inhibitors.


Pharmaceutical companies can adopt several strategies to address the challenges of biomarker testing practice and ensure a more efficient uptake of their treatments.

Promote testing fluency, education campaigns, public resources for patients and providers, communicate on laboratory qualifications

How IQVIA Can Help

To support pharmaceutical companies in addressing the challenges associated with biomarker testing, IQVIA offers a range of services and solutions, including:

  • Patient Journey Mapping: Identifying pain points and designing solutions for specific sub-populations.
  • Patient Flow Insights: Providing precise forecasts and scenario building by biomarker.
  • Qualitative Insights: Offering perspectives from healthcare providers, pathologists, and diagnostics laboratory directors on biomarker test volumes, turnaround times, testing technology, and more.
  • Treatment Dynamics: Analyzing patient initiation, flow, and medicine volume prescribed by biomarker.

As we continue to see advancements in biomarker research and its integration into clinical trials, it is imperative to stay informed about these developments to optimize treatment strategies and improve patient care.

Contact Us

For more information or to discuss how we can support your oncology initiatives, please reach out to us at:

Kristin Van den Daele: kristin.vandendaele@iqvia.com
Sophie Tigranoff : sophie.tigranoff@iqvia.com

1) AIM Specialty Health. (2021). Molecular Testing of Solid and Hematologic Tumors and Malignancies. Clinical Appropriateness Guidelines.

You may also be interested in

White Paper
Unlocking Pharmaceutical Potential: The Growing Role of Thai Clinics
Blog
Our Patient Advisory Board Spoke, IQVIA Listened: Why and How to Rethink Support Services
Infographic
IQVIA MIDAS® Patient: Redefining Pharmaceutical Strategy with Patient-Centric Intelligence
Article
The Value of Painting a Fuller Picture of the Patient Journey Within the U.S. Healthcare Network and Beyond
Case Study
IQVIA’s LAAD Plus Delivers Broader View of Providers and Patient Populations
Blog
Triple Negative Breast Cancer and Real-World Evidence
Prev
Next

Related solutions

Contact Us